Stock listing

NASDAQ:CLRB Cellectar Biosciences, Inc. Stock

Home listing (NASDAQ) of Cellectar Biosciences, Inc.

Follow Cellectar Biosciences, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:CLRB

$0.797 USD -0.088 (-10.0%)

Close on Nov 20, 2026

Past year -71.7% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.760 – $0.903 USDNov 20, 2026
Volume
80,371 sharesNov 20, 2026
Market cap
$8.00M USDAt the close on Nov 20, 2026 · price × 10.04M shares outstanding
52-week range
$0.760 – $4.700 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$143,250 USDMedian day 66,544 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Cellectar Biosciences, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:CLRB · Home$0.797 USD-0.088 (-10.0%)80,371$0.903$0.903$0.760$0.885Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CLRB · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.797-0.088-10.0%$0.903$0.903$0.76080,371
$0.885-0.035-3.8%$0.920$0.920$0.88050,165
$0.920-0.090-8.9%$1.010$1.078$0.89777,381
$1.010-0.130-11.4%$1.130$1.140$1.000126,562
$1.140-0.020-1.7%$1.190$1.205$1.13019,455
$1.160-0.050-4.1%$1.210$1.220$1.15050,906
$1.210-0.010-0.8%$1.260$1.300$1.19021,468
$1.220-0.060-4.7%$1.300$1.315$1.22063,370
$1.280+0.030+2.4%$1.300$1.310$1.260128,077
$1.250+0.100+8.7%$1.130$1.276$1.12576,951
$1.150-0.080-6.5%$1.210$1.270$1.110143,757
$1.230-0.080-6.1%$1.280$1.370$1.23087,792
$1.310+0.090+7.4%$1.240$1.310$1.227139,891
$1.220+0.015+1.2%$1.230$1.255$1.18066,544
$1.205-0.015-1.2%$1.205$1.205$1.18055,282
$1.220-0.020-1.6%$1.220$1.260$1.190111,805
$1.240+0.030+2.5%$1.220$1.260$1.20058,537
$1.2100.0000.0%$1.230$1.290$1.160161,564
$1.210-0.010-0.8%$1.250$1.270$1.190184,723
$1.220+0.050+4.3%$1.190$1.220$1.14058,227
$1.170-0.110-8.6%$1.280$1.280$1.17068,656
$1.280+0.050+4.1%$1.250$1.330$1.230134,955
$1.230+0.110+9.8%$1.130$1.240$1.120109,491
$1.120-0.020-1.8%$1.180$1.200$1.120195,300
$1.140-0.050-4.2%$1.190$1.280$1.120341,330
$1.190+0.010+0.8%$1.210$1.270$1.150382,262
$1.180-0.210-15.1%$1.440$1.465$1.150395,536
$1.390-0.040-2.8%$1.550$1.600$1.360539,388
$1.430-0.020-1.4%$1.450$1.470$1.400186,138
$1.450+0.050+3.6%$1.410$1.490$1.37091,480
$1.400-0.110-7.3%$1.570$1.570$1.340169,697
$1.5100.0000.0%$1.550$1.620$1.47042,570
$1.510-0.160-9.6%$1.660$1.729$1.460219,434
$1.670-0.110-6.2%$1.790$1.790$1.67060,681
$1.780-0.090-4.8%$1.950$1.975$1.78048,039
$1.870+0.030+1.6%$1.870$1.870$1.82030,182
$1.840+0.020+1.1%$1.920$1.920$1.82074,864
$1.820-0.010-0.5%$1.980$1.980$1.80686,034
$1.830+0.030+1.7%$1.800$1.890$1.80065,015
$1.800-0.275-13.3%$2.070$2.090$1.800124,577
$2.075-0.015-0.7%$2.130$2.150$1.96055,486
$2.090-0.140-6.3%$2.250$2.309$2.06072,943
$2.230-0.120-5.1%$2.360$2.370$2.174161,240
$2.350-0.030-1.3%$2.370$2.420$2.35050,009
$2.380-0.020-0.8%$2.390$2.440$2.37073,555
$2.400+0.050+2.1%$2.370$2.440$2.37071,669
$2.350+0.030+1.3%$2.320$2.390$2.32073,034
$2.320+0.010+0.4%$2.310$2.340$2.28033,372
$2.3100.0000.0%$2.330$2.450$2.29065,748
$2.310-0.060-2.5%$2.350$2.400$2.31038,394
$2.370+0.005+0.2%$2.350$2.400$2.35018,894
$2.365-0.045-1.9%$2.410$2.450$2.35044,376
$2.410+0.040+1.7%$2.460$2.470$2.37527,557
$2.370+0.020+0.9%$2.330$2.400$2.33026,575
$2.350-0.080-3.3%$2.390$2.440$2.34070,008
$2.430-0.030-1.2%$2.460$2.500$2.42048,766
$2.460-0.050-2.0%$2.480$2.540$2.45046,427
$2.510-0.020-0.8%$2.520$2.550$2.49017,294
$2.530-0.010-0.4%$2.550$2.550$2.51023,836
$2.5400.0000.0%$2.570$2.570$2.52010,321
$2.5400.0000.0%$2.460$2.590$2.46013,202
$2.540+0.020+0.8%$2.590$2.600$2.50016,671
$2.520-0.070-2.7%$2.560$2.590$2.50023,171
$2.5900.0000.0%$2.600$2.600$2.50026,653
$2.590-0.030-1.1%$2.620$2.620$2.50032,803

Splits

6 splits since 2011 · NASDAQ:CLRB · every price before a split is adjusted for it

DayRatioWhat
1-for-30Consolidation
1-for-10Consolidation
1-for-10Consolidation
1-for-10Consolidation
1-for-20Consolidation
1-for-153Consolidation
Ticker
NASDAQ:CLRB
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Cellectar Biosciences, Inc. news

Cellectar Biosciences, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
20 in the last 12 months · 164 in all · newest Nov 10, 2026 · oldest 2019
Calls
13 calls with a replay · 13 with a transcript · latest Nov 10, 2026
Decks
29 decks · latest October 2026

Where Cellectar Biosciences, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:CLRB · Home listing · This pageNASDAQUnited StatesUSD
BOATS:CLRBBOATSUnited StatesUSD
gettex:NV40gettexGermanyEUR
LS Exchange:A41BQ3LS ExchangeGermanyEUR
Frankfurt:NV40FrankfurtGermanyEUR
Lang & Schwarz:A41BQ3Lang & SchwarzGermanyEUR
Munich:NV40MunichGermanyEUR

Cash and shares

Aug 13, 2026 · Cellectar Biosciences — Investor Presentation (October 2026)

Shares outstanding
9,452,108
Fully diluted
61,804,329

The slide these figures come from

Valuation

Price/book 0.4× against a median of 0.9×: the lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$15.05M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
0.4×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.1×
Beta vs S&P 500
1.71

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Cellectar Biosciences, Inc. · NASDAQ:CLRBUS$8.00M−US$15.05Mn/an/an/a0.4×n/a0.1×1.71
Brainstorm Cell Therapeutics Inc. · OTC:BCLIUS$8.31MUS$10.08Mn/an/an/an/an/an/a0.40
Quantum Biopharma Ltd. Subordinate Voting Shares Class B · NASDAQ:QNTMUS$8.29M−US$3.20Mn/an/an/a0.7×n/a0.1×1.05
Moleculin Biotech, Inc. · NASDAQ:MBRXUS$8.22MUS$1.04Mn/an/an/a0.6×n/a0.0×0.42
IN8bio, Inc. · NASDAQ:INABUS$8.19M−US$3.03Mn/an/an/a0.6×n/a0.2×1.25
Intensity Therapeutics, Inc. · NASDAQ:INTSUS$8.19M−US$220,086n/an/an/a1.1×n/a0.0×1.30
Palatin Technologies, Inc. · AMEX:PTNUS$8.16MUS$4.58Mn/a12.7×n/a4.0×n/a0.1×0.61
Dare Bioscience, Inc. · NASDAQ:DAREUS$8.01M−US$2.65Mn/a−1.9×n/a3.4×−749.8%0.4×1.34
Immuron Limited · ASX:IMCUS$7.91MUS$1.94Mn/a0.4×n/a1.1×−49.8%0.0×n/a
Phio Pharmaceuticals Corp. · NASDAQ:PHIOUS$7.84M−US$2.77Mn/an/an/a0.9×n/a0.0×1.24
Vivesto AB · OMXSTO:VIVEUS$7.76MUS$6.12Mn/an/an/a0.5×n/a0.0×n/a
Median of the othersUS$8.17MUS$408,0900.4×0.9×−399.8%0.0×1.15

Forecasts

3 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
11.50 USD · Analysts' mean
EPS, year to Dec 2026
-2.21 · 3 analysts

Team and board

Officers

OfficerRole
James CarusoPresident, CEO and Director
Chad KoleanChief Financial Officer
Jarrod LongcorChief Operating Officer

Board

DirectorRole
Douglas J. SwirskyChairman of the Board
Andrew GuDirector
Asher Alban Chanan-KhanDirector
Frederick W. DriscollDirector
James CarusoPresident, CEO and Director
John NeisDirector

Events

Calls

CallWhenStatus
Cellectar Biosciences (NASDAQ:CLRB) Q3 2026 Earnings CallTue, Nov 10, 2026 · 8:30 AM ETReplay
Cellectar Biosciences (NASDAQ:CLRB) Q2 2026 Earnings CallThu, Aug 13, 2026 · 8:30 AM ETReplay
Cellectar Biosciences (NASDAQ:CLRB) Q1 2026 Earnings CallThu, May 14, 2026 · 8:30 AM ETReplay
Cellectar Biosciences (NASDAQ:CLRB) Q4 2025 Earnings CallWed, Mar 04, 2026 · 8:30 AM ETReplay
Cellectar Biosciences (NASDAQ:CLRB) Q3 2025 Earnings CallThu, Nov 13, 2025 · 8:30 AM ETReplay
Cellectar Biosciences (NASDAQ:CLRB) Q2 2025 Earnings CallThu, Aug 14, 2025 · 8:30 AM ETReplay
Cellectar Biosciences (NASDAQ:CLRB) Q1 2025 Earnings CallTue, May 13, 2025 · 8:30 PM ETReplay
Cellectar Biosciences (NASDAQ:CLRB) Q4 2024 Earnings CallThu, Mar 13, 2025 · 8:30 AM ETReplay
Cellectar Biosciences (NASDAQ:CLRB) Q3 2024 Earnings CallMon, Nov 18, 2024 · 8:00 AM ETReplay
Cellectar Biosciences (NASDAQ:CLRB) Q2 2024 Earnings CallTue, Aug 13, 2024 · 8:30 AM ETReplay
All 13 calls
CallWhenStatus
Cellectar Biosciences (NASDAQ:CLRB) Q1 2024 Earnings CallTue, May 14, 2024 · 8:30 AM ETReplay
Cellectar Biosciences (NASDAQ:CLRB) Q4 2023 Earnings CallWed, Mar 27, 2024 · 8:30 AM ETReplay
Cellectar Biosciences (NASDAQ:CLRB) Q3 2023 Earnings CallThu, Nov 02, 2023 · 8:30 AM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 10, 2026 · Before open−4.7%
Q2 2026Aug 13, 2026 · Before open−4.6%
Q1 2026May 14, 2026 · Before open+8.8%
Q4 2025Mar 4, 2026+3.4%
Q3 2025Nov 13, 2025 · Before open−18.0%
Q2 2025Aug 14, 2025 · Before open0.0%
Q1 2025May 13, 2025 · Before open−9.1%
Q4 2024Mar 25, 2025 · Before open−1.1%
Q3 2024Nov 18, 2024 · Before open−4.8%
Q2 2024Aug 13, 2024+7.5%
All 20 quarters
QuarterResultsShare move
Q1 2024May 14, 2024 · Before open+3.9%
Q4 2023Mar 27, 2024 · Before open−5.6%
Q3 2023Nov 13, 2023 · Before open+6.7%
Q2 2023Aug 14, 2023 · Before open+1.9%
Q1 2023May 4, 2023 · Before open−2.0%
Q4 2022Mar 9, 2023 · Before open−10.5%
Q3 2022Nov 3, 2022 · Before open−6.9%
Q2 2022Aug 5, 2022 · Before open+3.5%
Q1 2022May 10, 2022 · Before open−8.1%
Q4 2021Mar 21, 2022 · Before open+15.8%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (October 2026)Investor deck41 slidesOctober 2026
Investor Presentation (October 2026)Investor deck39 slidesOctober 2026
Investor Presentation (October 2026)Investor deck38 slidesOctober 2026
Q2 2026 Earnings PresentationEarnings38 slidesAug 13, 2026
Q1 2026 Earnings PresentationEarnings49 slidesMay 14, 2026
Q1 2025 Earnings PresentationEarnings41 slidesMay 13, 2025
Q1 2024 Earnings PresentationEarnings7 slidesMay 14, 2024
Investor Presentation (March 2022)Investor deck24 slidesMar 15, 2022
Investor Presentation (December 2020)Investor deck31 slidesDec 23, 2020
IPO Roadshow (May 2020)IPO roadshow34 slidesMay 20, 2020
All 29 decks
DeckKindSlidesDate
Technical Presentation (March 2020)Technical14 slidesMar 9, 2020
Technical Presentation (February 2020)Technical43 slidesFeb 20, 2020
Investor Presentation (January 2019)Investor deck30 slidesJan 29, 2019
Investor Presentation (January 2019)Investor deck33 slidesJan 7, 2019
Investor Presentation (October 2018)Investor deck29 slidesOct 2, 2018
Investor Presentation (September 2018)Investor deck21 slidesSep 6, 2018
IPO Roadshow (July 2018)IPO roadshow29 slidesJul 18, 2018
Investor Presentation (December 2016)Investor deck30 slidesDecember 2016
IPO Roadshow (November 2016)IPO roadshow29 slidesNov 14, 2016
Investor Presentation (September 2016)Investor deck25 slidesSeptember 2016
IPO Roadshow (March 2016)IPO roadshow27 slidesMar 25, 2016
Investor Presentation (January 2016)Investor deck30 slidesJan 11, 2016
Investor Presentation (August 2015)Investor deck23 slidesAugust 2015
IPO Roadshow (August 2014)IPO roadshow40 slidesAug 4, 2014
Technical Presentation (June 2014)Technical20 slidesJun 13, 2014
Technical Presentation (June 2014)Technical25 slidesJun 5, 2014
Investor Presentation (March 2014)Investor deck30 slidesMar 19, 2014
EMIT: Targeted Radiotherapy Conference 2013Conference27 slidesJan 31, 2013
Imaging in 2020 (Jackson Hole, WY)Conference48 slidesOct 3, 2012

Open Decks

Financings

RaiseDate
Warrant exercise of common stock upon exercise of existing warrants
Announced: about US$5.8M · US$5.25 a share · Warrants at US$6 for 60 months · Ladenburg Thalmann & Co. Inc.
Dealers: Ladenburg Thalmann & Co. Inc. (lead)
Use of proceeds: Working capital and general corporate purposes, Phase 1b study of CLR 125 in triple-negative breast cancer, and preparing a Conditional Marketing Authorization filing with the EMA
Oct 7, 2025
Public offering of class A Units and Class B Units
Closed: US$6.9M raised · US$5 a unit · Warrants at US$5.25 for 60 months · Ladenburg Thalmann & Co. Inc.
Dealers: Ladenburg Thalmann & Co. Inc. (lead)
Insiders: The offering includes participation from executive management
Use of proceeds: General corporate purposes, working capital and operating expenses, and a Phase 1b study of CLR 125 in triple-negative breast cancer
Jul 2, 2025
Warrant exercise of common stock upon exercise of existing warrants
Announced: about US$2.5M · US$0.3041 a share · Ladenburg Thalmann & Co. Inc.
Dealers: Ladenburg Thalmann & Co. Inc. (lead)
Use of proceeds: General corporate purposes, including working capital and operating expenses
Jun 5, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue0000000000
Cost of revenue213.6K291.7K192.4K238.9K227.6K207.9K189.4K82.3K1.55M356.7K
Gross profit-213.6K-291.7K-192.4K-238.9K-227.6K-207.9K-189.4K-82.3K-1.55M-356.7K
Research and development11.5M26.1M27.3M18.3M17.6M10.1M9.00M6.84M9.47M4.75M
Selling, general and administrative11.5M25.6M11.7M9.59M6.54M5.15M5.18M4.82M4.14M4.70M
Operating income-23.0M-51.8M-39.0M-28.8M-24.1M-15.3M-14.2M-13.3M-13.6M-9.45M
Depreciation and amortization213.6K291.7K192.4K148.4K149.9K141.5K132.8K82.3K1.55M356.7K
EBITDA-22.8M-51.5M-38.8M-28.7M-24.0M-15.1M-14.0M-13.2M-12.1M-9.09M
Interest expense301.0K2.28K10.9K42.7K29.7K16.6K7.90K
Income before tax-21.8M-44.5M-42.8M-31.9M-24.1M-15.1M-14.1M-13.2M-13.6M-6.18M
Income tax66.0K-60.0K-60.0K-152.2K-337.6K0000
Net income-21.8M-44.6M-42.8M-31.8M-24.1M-15.1M-14.1M-13.2M-13.6M-6.18M
Earnings per share, basic-8.35-36.52-3.50-4.51-4.35-0.76-1.84-5.23-10.70-2.14
Earnings per share, diluted-8.35-41.89-3.50-4.51-4.35-1.84-1.84-5.23-10.70-2.14

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents13.2M23.3M9.56M19.9M35.7M57.2M10.6M13.3M10.0M11.4M
Short-term investments55.0K55.0K55.0K
Inventory00
Current assets14.0M24.3M10.5M20.5M36.6M57.9M11.4M14.0M10.5M12.2M
Property, plant and equipment549.4K757.1K1.09M418.6K344.5K356.0K435.1K543.3K244.7K1.44M
Goodwill001.68M1.68M
Total assets15.0M25.5M12.1M21.6M37.2M58.7M12.3M15.1M12.9M15.3M
Accounts payable1.44M4.11M5.62M2.56M1.42M1.43M1.28M612.0K933.0K1.42M
Current liabilities4.75M9.39M25.4M11.5M3.99M3.56M2.77M1.62M2.11M1.63M
Long-term debt2.00K0
Total debt409.6K494.0K553.0K603.8K301.7K421.6K527.5K2.21K5.25K94.6K
Total liabilities5.06M9.80M25.9M12.1M4.16M3.86M3.19M1.79M2.12M1.78M
Shareholders' equity8.54M14.3M-15.2M8.15M29.1M54.8M9.06M13.3M10.8M13.5M
Shares outstanding4.24M1.54M20.7M9.39M6.11M45.4M9.39M4.73M1.67M10.4M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-23.1M-47.6M-32.4M-25.2M-22.6M-13.9M-11.7M-11.4M-11.0M-8.28M
Capital spending-5.88K-104.2K-864.0K-226.0K-141.4K-62.4K-24.5K-385.0K-346.7K-72.3K
Free cash flow-23.1M-47.7M-33.2M-25.4M-22.7M-14.0M-11.7M-11.8M-11.4M-8.35M
Cash from investing-5.88K-104.2K-864.0K-226.0K-141.4K-62.4K-24.5K-330.0K-346.7K-72.3K
Cash from financing13.0M61.4M22.9M9.61M1.25M60.5M9.02M15.0M9.93M15.9M
Dividends paid-2.24M-1.45M0
Share buybacks642.5K9.02M8.19M3.71M-1
Change in cash-10.1M13.7M-10.3M-15.8M-21.5M46.6M-2.70M3.25M-1.44M7.59M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
8-K · Current reportNov 10, 2026ResultsSEC
10-Q · Quarterly reportNov 10, 2026Quarterly reportSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 13, 2026Big-stake noticeSEC
8-K · Current reportAug 13, 2026ResultsSEC
10-Q · Quarterly reportAug 13, 2026Quarterly reportSEC
Show 200 filings
FilingDateTypeFiled with
SCHEDULE 13G · Big-stake noticeAug 4, 2026Big-stake noticeSEC
4/A · Change in ownership, amendedJul 10, 2026Insider tradeSEC
8-K · Current reportJul 10, 2026Management or board changeSEC
4 · Change in ownershipJul 8, 2026Insider tradeSEC
4 · Change in ownershipJul 8, 2026Insider tradeSEC
4 · Change in ownershipJul 8, 2026Insider tradeSEC
4 · Change in ownershipJul 8, 2026Insider tradeSEC
4 · Change in ownershipJul 8, 2026Insider tradeSEC
4 · Change in ownershipJul 8, 2026Insider tradeSEC
4 · Change in ownershipJul 8, 2026Insider tradeSEC
4 · Change in ownershipJul 8, 2026Insider tradeSEC
4 · Change in ownershipJul 8, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 9, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeJun 5, 2026Big-stake noticeSEC
424B3 · ProspectusJun 2, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveJun 2, 2026Other filingsSEC
CORRESP · Letter to the SECMay 29, 2026Other filingsSEC
S-1/A · Registration statement, amendedMay 29, 2026Offer documentSEC
DEFA14A · Additional proxy materialMay 28, 2026Meeting noticeSEC
DEF 14A · Proxy statementMay 28, 2026Meeting noticeSEC
UPLOAD · Letter from the SECMay 22, 2026Other filingsSEC
S-1 · Registration statementMay 19, 2026Offer documentSEC
PRE 14A · Preliminary proxy statementMay 18, 2026Meeting noticeSEC
8-K · Current reportMay 18, 2026Management or board changeSEC
8-K · Current reportMay 14, 2026ResultsSEC
10-Q · Quarterly reportMay 14, 2026Quarterly reportSEC
4 · Change in ownershipMay 11, 2026Insider tradeSEC
4 · Change in ownershipMay 11, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeMay 11, 2026Big-stake noticeSEC
8-K · Current reportMay 8, 2026Material contractSEC
424B5 · ProspectusMay 6, 2026Offer documentSEC
10-K/A · Annual report, amendedApr 30, 2026Annual reportSEC
8-K · Current reportMar 4, 2026ResultsSEC
10-K · Annual reportMar 4, 2026Annual reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 10, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 4, 2026Big-stake noticeSEC
4 · Change in ownershipDec 16, 2025Insider tradeSEC
424B3 · ProspectusNov 21, 2025Offer documentSEC
SCHEDULE 13G · Big-stake noticeNov 14, 2025Big-stake noticeSEC
8-K · Current reportNov 13, 2025ResultsSEC
10-Q · Quarterly reportNov 13, 2025Quarterly reportSEC
S-1 · Registration statementOct 20, 2025Offer documentSEC
8-K · Current reportOct 10, 2025ResultsSEC
8-K · Current reportOct 6, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
8-K · Current reportAug 14, 2025ResultsSEC
10-Q · Quarterly reportAug 14, 2025Quarterly reportSEC
SCHEDULE 13G · Big-stake noticeAug 8, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJul 8, 2025Big-stake noticeSEC
4 · Change in ownershipJul 3, 2025Insider tradeSEC
4 · Change in ownershipJul 3, 2025Insider tradeSEC
4 · Change in ownershipJul 3, 2025Insider tradeSEC
EFFECT · Notice that a registration is effectiveJul 2, 2025Other filingsSEC
424B4 · ProspectusJul 1, 2025Offer documentSEC
CORRESP · Letter to the SECJun 30, 2025Other filingsSEC
CORRESP · Letter to the SECJun 30, 2025Other filingsSEC
S-1/A · Registration statement, amendedJun 30, 2025Offer documentSEC
8-K · Current reportJun 26, 2025Current reportSEC
S-1 · Registration statementJun 26, 2025Offer documentSEC
8-K · Current reportJun 25, 2025Current reportSEC
8-K · Current reportJun 18, 2025Current reportSEC
8-K · Current reportJun 13, 2025Meeting outcomeSEC
DEFA14A · Additional proxy materialJun 11, 2025Meeting noticeSEC
8-K · Current reportJun 5, 2025Material contractSEC
UPLOAD · Letter from the SECMay 29, 2025Other filingsSEC
DRS · Draft registration statementMay 23, 2025Offer documentSEC
8-K · Current reportMay 13, 2025ResultsSEC
10-Q · Quarterly reportMay 13, 2025Quarterly reportSEC
8-K · Current reportMay 1, 2025Current reportSEC
DEFA14A · Additional proxy materialApr 28, 2025Meeting noticeSEC
ARS · Annual report to shareholdersApr 28, 2025Annual reportSEC
DEF 14A · Proxy statementApr 28, 2025Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 18, 2025Meeting noticeSEC
8-K · Current reportMar 17, 2025Management or board changeSEC
8-K · Current reportMar 13, 2025ResultsSEC
10-K · Annual reportMar 13, 2025Annual reportSEC
4 · Change in ownershipMar 12, 2025Insider tradeSEC
4 · Change in ownershipFeb 18, 2025Insider tradeSEC
4 · Change in ownershipFeb 18, 2025Insider tradeSEC
4 · Change in ownershipFeb 18, 2025Insider tradeSEC
4 · Change in ownershipFeb 18, 2025Insider tradeSEC
4 · Change in ownershipFeb 18, 2025Insider tradeSEC
4 · Change in ownershipFeb 18, 2025Insider tradeSEC
4 · Change in ownershipFeb 18, 2025Insider tradeSEC
4 · Change in ownershipFeb 18, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2025Big-stake noticeSEC
424B3 · ProspectusFeb 7, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveFeb 7, 2025Other filingsSEC
CORRESP · Letter to the SECFeb 4, 2025Other filingsSEC
UPLOAD · Letter from the SECFeb 3, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 3, 2025Big-stake noticeSEC
8-K · Current reportJan 31, 2025Current reportSEC
S-1 · Registration statementJan 29, 2025Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 27, 2025Big-stake noticeSEC
8-K · Current reportJan 14, 2025Current reportSEC
8-K · Current reportDec 11, 2024Current reportSEC
8-K · Current reportNov 18, 2024ResultsSEC
10-Q · Quarterly reportNov 18, 2024Quarterly reportSEC
8-K · Current reportNov 15, 2024Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
NT 10-Q · Late filing noticeNov 13, 2024Explanation requestSEC
8-K · Current reportNov 1, 2024Current reportSEC
10-Q · Quarterly reportOct 29, 2024Quarterly reportSEC
10-Q/A · Quarterly report, amendedOct 29, 2024Quarterly reportSEC
10-K/A · Annual report, amendedOct 29, 2024Annual reportSEC
8-K · Current reportAug 23, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedAug 14, 2024Big-stake noticeSEC
NT 10-Q · Late filing noticeAug 14, 2024Explanation requestSEC
8-K · Current reportAug 13, 2024ResultsSEC
8-K · Current reportAug 9, 2024Current reportSEC
EFFECT · Notice that a registration is effectiveJul 24, 2024Other filingsSEC
8-K · Current reportJul 23, 2024ResultsSEC
CORRESP · Letter to the SECJul 22, 2024Other filingsSEC
8-K · Current reportJul 22, 2024Material contractSEC
SC 13G/A · Big-stake notice, amendedJul 11, 2024Big-stake noticeSEC
8-K · Current reportJul 11, 2024Current reportSEC
8-K · Current reportJun 25, 2024Material contractSEC
4 · Change in ownershipJun 18, 2024Insider tradeSEC
4 · Change in ownershipJun 18, 2024Insider tradeSEC
4 · Change in ownershipJun 18, 2024Insider tradeSEC
4 · Change in ownershipJun 18, 2024Insider tradeSEC
4 · Change in ownershipJun 18, 2024Insider tradeSEC
4 · Change in ownershipJun 18, 2024Insider tradeSEC
4 · Change in ownershipJun 18, 2024Insider tradeSEC
4 · Change in ownershipJun 18, 2024Insider tradeSEC
4 · Change in ownershipJun 18, 2024Insider tradeSEC
4 · Change in ownershipJun 18, 2024Insider tradeSEC
8-K · Current reportJun 14, 2024Management or board changeSEC
UPLOAD · Letter from the SECMay 31, 2024Other filingsSEC
S-3 · Registration statementMay 24, 2024Offer documentSEC
DEFR14AMay 16, 2024Meeting noticeSEC
8-K · Current reportMay 14, 2024ResultsSEC
10-Q · Quarterly reportMay 14, 2024Quarterly reportSEC
ARS · Annual report to shareholdersApr 26, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 26, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 26, 2024Meeting noticeSEC
SC 13G/A · Big-stake notice, amendedApr 25, 2024Big-stake noticeSEC
10-K/A · Annual report, amendedApr 1, 2024Annual reportSEC
8-K · Current reportMar 27, 2024ResultsSEC
10-K · Annual reportMar 27, 2024Annual reportSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 7, 2024Big-stake noticeSEC
8-K · Current reportFeb 2, 2024Current reportSEC
SC 13G · Big-stake noticeJan 31, 2024Big-stake noticeSEC
8-K · Current reportJan 25, 2024Current reportSEC
8-K · Current reportJan 9, 2024Current reportSEC
4 · Change in ownershipDec 12, 2023Insider tradeSEC
4 · Change in ownershipDec 12, 2023Insider tradeSEC
4 · Change in ownershipDec 12, 2023Insider tradeSEC
4 · Change in ownershipDec 12, 2023Insider tradeSEC
4 · Change in ownershipDec 12, 2023Insider tradeSEC
SC 13G · Big-stake noticeDec 7, 2023Big-stake noticeSEC
SC 13G · Big-stake noticeDec 5, 2023Big-stake noticeSEC
8-K · Current reportNov 29, 2023Current reportSEC
10-Q · Quarterly reportNov 13, 2023Quarterly reportSEC
8-K · Current reportNov 2, 2023ResultsSEC
EFFECT · Notice that a registration is effectiveOct 31, 2023Other filingsSEC
424B3 · ProspectusOct 30, 2023Offer documentSEC
8-K · Current reportOct 27, 2023Meeting outcomeSEC
CORRESP · Letter to the SECOct 26, 2023Other filingsSEC
S-3/A · Registration statement, amendedOct 25, 2023Offer documentSEC
UPLOAD · Letter from the SECOct 12, 2023Other filingsSEC
S-3 · Registration statementOct 5, 2023Offer documentSEC
DEF 14A · Proxy statementOct 2, 2023Meeting noticeSEC
PRE 14A · Preliminary proxy statementSep 22, 2023Meeting noticeSEC
DSep 22, 2023Other filingsSEC
8-K · Current reportSep 8, 2023Material contractSEC
8-K · Current reportAug 21, 2023Current reportSEC
8-K · Current reportAug 14, 2023ResultsSEC
10-Q · Quarterly reportAug 14, 2023Quarterly reportSEC
8-K · Current reportJun 29, 2023Current reportSEC
8-K · Current reportJun 29, 2023Management or board changeSEC
4 · Change in ownershipJun 28, 2023Insider tradeSEC
4 · Change in ownershipJun 28, 2023Insider tradeSEC
4 · Change in ownershipJun 28, 2023Insider tradeSEC
4 · Change in ownershipJun 28, 2023Insider tradeSEC
4 · Change in ownershipJun 28, 2023Insider tradeSEC
DEFA14A · Additional proxy materialJun 20, 2023Meeting noticeSEC
8-K/A · Current report, amendedJun 20, 2023Current reportSEC
DEFA14A · Additional proxy materialJun 14, 2023Meeting noticeSEC
8-K · Current reportJun 14, 2023Current reportSEC

This page holds 200 of 1,000 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Cellectar Biosciences, Inc.’s releases · as of Nov 6, 2026

Common shares
10,039,183
Fully diluted
10,039,183

Fully diluted

LineSharesAs of
Common shares10,039,183Nov 6, 2026

Warrants and options

Lot
Warrants · US$5.25 · expire about Jul 2030

Share count over time

CountShares
Nov 6, 202610,039,183
Sep 30, 202610,039,183

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Empery Asset Management, LP955K9.5%US$1.76MSep 30, 2026
Stonepine Capital Management, LLC749K7.5%US$1.38MSep 30, 2026
Caligan Partners LP470K4.7%US$865KSep 30, 2026
Janus Henderson466K4.6%US$860KSep 30, 2026
Stempoint Capital LP447K4.5%US$823KSep 30, 2026
Vanguard357K3.6%US$657KSep 30, 2026
Bleichroeder LP289K2.9%US$531KSep 30, 2026
Balyasny Asset Management L.P.220K2.2%US$405KSep 30, 2026
Nantahala Capital Management, LLC220K2.2%US$405KSep 30, 2026
Silverarc Capital Management, LLC151K1.5%US$278KSep 30, 2026
All 27 holders
HolderSharesOf the companyValueAs of
Boothbay Fund Management, LLC85,0690.85%US$157KSep 30, 2026
Diadema Partners LP71,3820.71%US$131KSep 30, 2026
Geode Capital69,3010.69%US$128KSep 30, 2026
Sequoia Financial Advisors, LLC32,0500.32%US$58,972Sep 30, 2026
Persistent Asset Partners Ltd20,5280.20%US$37,772Sep 30, 2026
Acadian Asset Management LLC16,5770.17%US$30,000Sep 30, 2026
Northern Trust14,8390.15%US$27,304Sep 30, 2026
BlackRock4,7350.05%US$8,712Sep 30, 2026
UBS3,2180.03%US$5,921Sep 30, 2026
Nuveen1,1970.01%US$2,179Sep 30, 2026
Morgan Stanley500<0.01%US$920Sep 30, 2026
TD63<0.01%US$117Sep 30, 2026
Osaic Holdings, Inc.7<0.01%US$11Sep 30, 2026
SBI Securities Co., Ltd.6<0.01%US$11Sep 30, 2026
Key Financial Inc3<0.01%US$6Sep 30, 2026
Danske Bank A/S2<0.01%US$4Sep 30, 2026
Fidelity2<0.01%US$4Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund184K1.8%US$512KJun 30, 2026
Vanguard Extended Market Index Fund143K1.4%US$398KJun 30, 2026
Fidelity Extended Market Index Fund26,9770.27%US$84,708May 31, 2026
Fidelity Series Total Market Index Fund5,6410.06%US$17,713May 31, 2026
Fidelity Total Market Index Fund2,0640.02%US$6,481May 31, 2026
Fidelity Nasdaq Composite Index Fund200<0.01%US$628May 31, 2026
Blackstone Alternative Multi-Strategy Fund1<0.01%US$3Jun 30, 2026

Insider trades

TradeTradeSharesPriceValueDate
Caruso James V
Director, Officer: Chief Executive Officer
Buy8,680USD 2.88US$24,998May 7, 2026
Longcor Jarrod
Officer: Chief Operating Officer
Buy8,680USD 2.88US$24,998May 7, 2026

Big stakes

StakeStakeSharesDateFiling
Balyasny Asset Management L.P.9.99%944KSep 30, 2026Schedule 13G
Silverarc Capital Management, LLC9.99%851KJun 30, 2026Schedule 13G
Bleichroeder LP9.99%808KJun 30, 2026Schedule 13G
Empery Asset Management, LP9.99%864KJun 30, 2026Schedule 13G
Janus Henderson Group PLC9.99%798KMay 29, 2026Schedule 13G
Stempoint Capital LP9.90%846KJun 30, 2026Schedule 13G
Stonepine Capital Management, LLC9.90%863KMay 4, 2026Schedule 13G
Caligan Partners LP5.90%470KJun 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Douglas J. Swirsky
Other companies: MaxCyte, Inc. (CHIEF FINANCIAL OFFICER · Since at least Mar 15, 2024)
Director · Since at least Jun 14, 2024
Frederick W. Driscoll
Other companies: Lite Strategy, Inc. (Chairperson, Non-Executive Director · Since at least Jul 15, 2025)
Director · Since at least Jul 7, 2026
Andrew GuDirector · Since at least May 14, 2026
Asher Alban Chanan-KhanDirector · Since at least Nov 5, 2026
Cameron SzakacsVP of Clinical Development · Nov 24, 2014 – Nov 24, 2014 · Past
Chad KoleanChief Financial Officer · Since at least Nov 5, 2026
Darrell Shane LeaChief Commercial Officer · Nov 21, 2022 – Jun 14, 2024 · Past
James CarusoPresident, CEO and Director · Since at least May 7, 2026
Jamey P WeichertChief Scientific Officer · Aug 14, 2014 – May 12, 2016 · Past
Jarrod LongcorChief Operating Officer · Since at least May 11, 2026
All 12 people
PersonSeat
John NeisDirector · Since at least Apr 20, 2016
Stefan LorenDirector · Jun 14, 2024 – Feb 14, 2025 · Past

Open People

Log in to ask 6ix AI your own questions about Cellectar Biosciences, Inc.